Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME, page-6

This is really positive too:

An exploratory subgroup analysis was conducted in patients with a prior anti-VEGF-A treatment history
of only receiving previous Eylea to assess the effects of OPT-302 combination therapy following the most
optimal first-line standard of care used to achieve maximal VEGF-A inhibition. In this subgroup, the mean
change in BCVA at week 12 compared to baseline was 8.6 letters for OPT-302 + Eylea and 5.0 letters in
patients who continued on Eylea monotherapy. The proportion of patients in the subgroup gaining ≥10
and ≥15 letters from baseline to week 12 was 50% and 16.7% in the OPT-302 combination group
respectively and 0% for both parameters in the Eylea control. The percentage of patients losing 1 or
more letters from baseline to week 12 was 8.3% in the OPT-302 + Eylea group, and 12.5% for the Eylea
control.